Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | CHIEF SCIENTIFIC OFFICER | February 19, 2025 | February 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date February 19, 2025 · Filed February 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,794 |
Reported balance
After 2025-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-19 · Tax withholding · Disposed 2,276 · Balance 59,794 F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 26, 2025 23:44 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 2,276 | $0.48 | $1,083.38 |
DisclosureSEC source: 0001415889-25-005727 · form4-02262025_110225.xml · nonDerivative · entry 1 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,794 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2024 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001415889-25-004222 · form4-02142025_110252.xml · derivative · entry 1 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001415889-24-030069 · form4-12232024_041227.xml · derivative · entry 1 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-12-19 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:37 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 90,102 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001415889-24-004236 · form4-02162024_110255.xml · derivative · entry 3 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,102 Underlying: Common Stock · 90,102 shares Expires 2034-02-14 F4 · derivative.exercise_date: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:37 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001415889-24-004236 · form4-02162024_110255.xml · derivative · entry 2 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:37 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 2,843 | $0.79 | $2,245.97 |
DisclosureSEC source: 0001415889-24-004236 · form4-02162024_110255.xml · nonDerivative · entry 1 van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,070 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-23-010736 · doc4.xml · derivative · entry 3 van der Horst Edward · CIK 0001957499 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 17,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010736 · doc4.xml · nonDerivative · entry 2 van der Horst Edward · CIK 0001957499 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,438 F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 23,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010736 · doc4.xml · nonDerivative · entry 1 van der Horst Edward · CIK 0001957499 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,738 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. Read SEC document |
| February 15, 2023 Filed Sep 11, 2023 21:33 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 9,525 | $1.50 | $14,287.50 |
DisclosureSEC source: 0001209191-23-048967 · doc4.xml · nonDerivative · entry 1 van der Horst Edward · CIK 0001957499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,913 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.